PE20211593A1 - Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, produccion y formulacion del mismo - Google Patents
Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, produccion y formulacion del mismoInfo
- Publication number
- PE20211593A1 PE20211593A1 PE2021000859A PE2021000859A PE20211593A1 PE 20211593 A1 PE20211593 A1 PE 20211593A1 PE 2021000859 A PE2021000859 A PE 2021000859A PE 2021000859 A PE2021000859 A PE 2021000859A PE 20211593 A1 PE20211593 A1 PE 20211593A1
- Authority
- PE
- Peru
- Prior art keywords
- pirimidin
- pyridin
- methyl carbamate
- ilo
- fluorobenzyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 title abstract 3
- -1 2-FLUOROBENZYL Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000080 wetting agent Substances 0.000 abstract 2
- KFZMGEQAYNKOFK-YZRHJBSPSA-N (214C)propan-2-ol Chemical compound [14CH](C)(C)O KFZMGEQAYNKOFK-YZRHJBSPSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 239000012296 anti-solvent Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18213115 | 2018-12-17 | ||
| PCT/EP2019/085255 WO2020126983A1 (en) | 2018-12-17 | 2019-12-16 | Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211593A1 true PE20211593A1 (es) | 2021-08-18 |
Family
ID=64744472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000859A PE20211593A1 (es) | 2018-12-17 | 2019-12-16 | Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, produccion y formulacion del mismo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12172996B2 (https=) |
| EP (1) | EP3898624A1 (https=) |
| JP (1) | JP7529667B2 (https=) |
| KR (1) | KR102872983B1 (https=) |
| CN (1) | CN113207290B (https=) |
| AR (1) | AR116912A1 (https=) |
| AU (1) | AU2019409269B2 (https=) |
| BR (1) | BR112021009122A2 (https=) |
| CA (1) | CA3123360A1 (https=) |
| CL (1) | CL2021001580A1 (https=) |
| CO (1) | CO2021007668A2 (https=) |
| IL (1) | IL283976B2 (https=) |
| JO (1) | JOP20210155B1 (https=) |
| MX (1) | MX2021007090A (https=) |
| PE (1) | PE20211593A1 (https=) |
| SG (1) | SG11202104953VA (https=) |
| TW (1) | TWI830835B (https=) |
| UA (1) | UA129677C2 (https=) |
| WO (1) | WO2020126983A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI830835B (zh) | 2018-12-17 | 2024-02-01 | 德商亞德維瑞醫藥有限公司 | 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物 |
| EP4099987B1 (en) | 2020-02-03 | 2025-03-12 | Adverio Pharma GmbH | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| EP3925953A1 (en) | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| WO2025114276A1 (en) | 2023-12-01 | 2025-06-05 | Krka, D.D., Novo Mesto | Solid oral composition comprising vericiguat |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2745813B1 (fr) | 1996-03-07 | 1998-05-07 | Rhone Poulenc Chimie | Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| UY33041A (es) | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
| PL2604608T3 (pl) | 2009-11-27 | 2016-02-29 | Adverio Pharma Gmbh | Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| ES2603028T3 (es) * | 2011-11-25 | 2017-02-23 | Adverio Pharma Gmbh | Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos |
| MX2015010725A (es) * | 2013-02-21 | 2016-05-31 | Adverio Pharma Gmbh | Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato. |
| PL2792682T3 (pl) | 2013-04-19 | 2017-04-28 | Zach System | Sposób wytwarzania stałej postaci octanu abirateronu |
| WO2016113415A1 (en) * | 2015-01-16 | 2016-07-21 | Sandoz Ag | Process for the preparation of riociguat essentially free from genotoxic impurities |
| WO2017025981A1 (en) * | 2015-08-13 | 2017-02-16 | Msn Laboratories Private Limited | Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof |
| TWI830835B (zh) | 2018-12-17 | 2024-02-01 | 德商亞德維瑞醫藥有限公司 | 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物 |
| CN113272286B (zh) | 2019-01-22 | 2024-04-16 | 阿德弗里奥药品有限责任公司 | 制备4-(2,2,3,3-四氟丙基)吗啉的方法 |
| EP4099987B1 (en) * | 2020-02-03 | 2025-03-12 | Adverio Pharma GmbH | Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
| EP3925953A1 (en) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
-
2019
- 2019-12-13 TW TW108145683A patent/TWI830835B/zh active
- 2019-12-16 KR KR1020217018155A patent/KR102872983B1/ko active Active
- 2019-12-16 SG SG11202104953VA patent/SG11202104953VA/en unknown
- 2019-12-16 EP EP19818086.1A patent/EP3898624A1/en active Pending
- 2019-12-16 WO PCT/EP2019/085255 patent/WO2020126983A1/en not_active Ceased
- 2019-12-16 PE PE2021000859A patent/PE20211593A1/es unknown
- 2019-12-16 IL IL283976A patent/IL283976B2/en unknown
- 2019-12-16 CN CN201980082044.4A patent/CN113207290B/zh active Active
- 2019-12-16 US US17/414,658 patent/US12172996B2/en active Active
- 2019-12-16 JP JP2021534766A patent/JP7529667B2/ja active Active
- 2019-12-16 AU AU2019409269A patent/AU2019409269B2/en active Active
- 2019-12-16 MX MX2021007090A patent/MX2021007090A/es unknown
- 2019-12-16 UA UAA202104115A patent/UA129677C2/uk unknown
- 2019-12-16 BR BR112021009122-0A patent/BR112021009122A2/pt unknown
- 2019-12-16 CA CA3123360A patent/CA3123360A1/en active Pending
- 2019-12-17 AR ARP190103698A patent/AR116912A1/es unknown
-
2021
- 2021-06-11 CO CONC2021/0007668A patent/CO2021007668A2/es unknown
- 2021-06-16 CL CL2021001580A patent/CL2021001580A1/es unknown
- 2021-06-16 JO JOJO/P/2021/0155A patent/JOP20210155B1/ar active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021007090A (es) | 2021-08-11 |
| CL2021001580A1 (es) | 2021-12-03 |
| SG11202104953VA (en) | 2021-06-29 |
| JOP20210155B1 (ar) | 2025-10-01 |
| AU2019409269A1 (en) | 2021-06-03 |
| JP7529667B2 (ja) | 2024-08-06 |
| IL283976B1 (en) | 2024-12-01 |
| TW202039488A (zh) | 2020-11-01 |
| IL283976B2 (en) | 2025-04-01 |
| CN113207290A (zh) | 2021-08-03 |
| JOP20210155A1 (ar) | 2023-01-30 |
| EP3898624A1 (en) | 2021-10-27 |
| KR102872983B1 (ko) | 2025-10-17 |
| BR112021009122A2 (pt) | 2021-08-10 |
| US20220048907A1 (en) | 2022-02-17 |
| UA129677C2 (uk) | 2025-07-02 |
| WO2020126983A1 (en) | 2020-06-25 |
| IL283976A (en) | 2021-07-29 |
| CA3123360A1 (en) | 2020-06-25 |
| JP2022515376A (ja) | 2022-02-18 |
| AR116912A1 (es) | 2021-06-23 |
| AU2019409269B2 (en) | 2025-04-03 |
| TWI830835B (zh) | 2024-02-01 |
| CO2021007668A2 (es) | 2021-07-19 |
| CN113207290B (zh) | 2024-04-09 |
| KR20210104703A (ko) | 2021-08-25 |
| US12172996B2 (en) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211593A1 (es) | Producto del compuesto activo carbamato de metil {4,6-diamino-2-[5-fluor-1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-ilo} que tiene propiedades mejoradas, produccion y formulacion del mismo | |
| AR121135A2 (es) | Solución no acuosa de regulador(es) de crecimiento vegetal y solvente(s) orgánicos polar(es) y/o semi-polar(es) | |
| EP4311541A3 (en) | Cryoprotective agents for particulate formulations | |
| AR099630A1 (es) | Preparación de un inhibidor de mek y formulación que lo comprende | |
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| AR045490A1 (es) | Glucopiranosiloxi - pirazoles, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| BR112017007953A2 (pt) | forma cristalina de um bissulfato inibidor de jak quinase e método de preparação desse | |
| CL2013002243A1 (es) | Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica. | |
| PE20171108A1 (es) | Metodos de purificacion de cannabinoides, composiciones y kits de los mismos | |
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| AR086792A1 (es) | Compuestos para el tratamiento de la adiccion | |
| JP2014521673A5 (https=) | ||
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| CL2012000043A1 (es) | Métodos para producir azufre micronizado que comprenden fundir el azufre, preparar una solución dispersante, mantenerla a presión y subir su temperatura a una mayor a la de fusión del azufre, mezclarla con el azufre para formar una suspensión de azufre emulsionado, enfriar, retirar la solución dispersante y secar las partículas. | |
| JP2016518448A5 (https=) | ||
| AR064636A1 (es) | Nuevos compuestos 621 | |
| AR100263A1 (es) | Composición para alimentos líquidos y bebidas | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR088296A1 (es) | Citramida de rasagilina, proceso de preparación y composicion farmaceutica | |
| BR112016007133A2 (pt) | coformulações co de bifentrina com agentes de proteção de colheita de alto ponto de fusão para uso com fertilizantes líquidos | |
| AR096045A1 (es) | Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco | |
| PE20131098A1 (es) | Proedimiento de preparacion de la sal de l-arginina de perindoprilo |